Dalfampridine with nerve stimulation and exercise after spinal cord injury
Tests dalfampridine plus stimulation and training in spinal cord injury.
Key facts
- Who runs it
- Shirley Ryan AbilityLab
- Where
- Chicago, United StatesSee the site
- Trial code
- Registry title
- Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 27 people, planned
- Started
- 1 Feb 2025
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dalfampridine
- Placebo
- STDP stimulation
- Exercise training
- Record updated
- 3 June 2026
Who can take part
The trial is looking for adults with a spinal cord injury at least 6 months ago who can still slightly move ankle and hip muscles. It tests Dalfampridine (4-AP) twice a day with nerve stimulation and training.
- Age
- 18-85 years
- Sex
- Men and women
- Disease stage
- Spinal cord injury 6 months after injury, at or above L2, ASIA A, B, C, or D, complete or incomplete. You must be able to make a small visible contraction of the muscles that lift the foot and bend the hip.
- Earlier treatment
- People taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, PR Interval prolonging drugs, or nervous system drugs that make seizures more likely cannot join.
- Main reasons for not taking part
- History of seizures or epilepsy, head injury, stroke, or a brain lesion
- Any history of kidney problems
- Pregnancy, or unsure of pregnancy and not wanting a pregnancy test
- Ongoing cord compression, syrinx, or spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
- Metal plate in skull, scalp shrapnel, cochlear implants, or aneurysm clips
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Male and females between ages 18-85 years
- SCI 6 months post injury
- Spinal Cord injury at or above L2
- ASIA A, B, C, or D, complete or incomplete
- The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles
Who cannot take part
- Any debilitating disease prior to the SCI that caused exercise intolerance
- Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)
- Individuals with scalp shrapnel, cochlear implants, or aneurysm clips
- Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs
- Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease
- Any history of renal impairment
- History of head injury or stroke
- Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
- History of seizures or epilepsy
- Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
- If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test
- Premorbid, ongoing major depression or psychosis, altered cognitive status
- Pregnant females
- Metal plate in skull
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- SCI - spinal cord injury
This trial is currently available in United States.
- Shirley Ryan AbilityLabChicago, United StatesContact: Monica Perez, PT, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
The 2 groups in the trial
- 4-AP(AM) + STDP stimulation + training + 4-AP(PM)Treatment being tested
The effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of twice-daily-dosing 4-AP, STDP stimulation and training.
Treatment: Dalfampridine, STDP stimulation, and Exercise training
- Placebo(AM) + STDP stimulation + training + Placebo(PM)Placebo, for comparison
The effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of twice-daily-dosing Placebo, STDP stimulation and training.
Treatment: Placebo, STDP stimulation, and Exercise training
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury
- Plain-language title
- Dalfampridine with nerve stimulation and exercise after spinal cord injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06853015, who can take part
- Record updated
- 3 June 2026